Table 1.
Formulation parameters, particle sizes, zeta potential, poly dispersity index, and percentage encapsulation efficiency of the ellagic acid nanosponges (n = 3, mean ± SD)
| Techniques | Variables (β-CD and DPC ratio) | Bioactive loaded CDNS | Average diameter | Zeta potential | Polydispersity index | % Encapsulation efficiency ± SD |
|---|---|---|---|---|---|---|
| Melt method | 1:4 | EANS1 | 202 | -21.6 | 0.751 | 73 ± 15.39* |
| 1:6 | EANS2 | 406 | -14.5 | 0.648 | 53 ± 8.178 | |
| Microwave assisted synthesis | 1:4 | EANS3 | 353 | -15.4 | 0.587 | 58 ± 3.789 |
| 1:6 | EANS4 | 406 | -20.8 | 0.225 | 46 ± 1 |
Statistical analysis from the one-way ANOVA (and nonparametric) Kruskal–Wallis test (encapsulation efficiency: Kruskal–Wallis statistics 8.167) followed by Dunn's Multiple Comparison Test with *p < 0.05
SD, Standard deviation; EANS1, EANS2 and EANS3, EANS4 represent drug loaded nanosponges prepared at molar ratios 1:4, 1:6 of β-CD: DPC via melt method and microwave assisted synthesis, respectively